SiliCycle Inc. obtains its retail license for cannabis products
by CM Staff
It is in a factory located in the Technological Park of Metropolitan Quebec that the production of hemp and cannabis extracts takes place.
QUEBEC CITY — SiliCycle Inc., a company working in the health field, founded and established in Quebec City, takes a major step by announcing that it has obtained its retail license for cannabis products, topical products, cannabis extracts and edibles from Health Canada. It is with the contribution of its subsidiary PurCann Pharma and under the trademarks “Tyche”, “Oovie” and “Ollopa” that the first products will be available on the Quebec and Canadian markets, starting from August for Tyche and subsequently for Oovie and Ollopa.
PurCann Pharma aims to improve the health and well-being of individuals by trying to become the largest Canadian processor of products, including pharmaceuticals, derived from hemp and cannabis. The development of innovative applications of cannabis products is at the heart of the company’s activities.
PurCann Pharma was founded with the objective of serving the pharmaceutical, nutraceutical, cosmetic, food and animal health industries with innovative products derived from hemp and cannabis.
Products to hit the market this summer will first be CBD oil in capsules, sprays and liquids under the brand name “Tyche.”
PurCann Pharma can process over 200 tonnes of hemp and cannabis per year to produce nearly 25 million bottles of oil. The company also plans to double processing in 2022 to reach 400 tonnes per year.
It is in a factory located in the Technological Park of Metropolitan Quebec that the production of hemp and cannabis extracts takes place. Built in 2009 and recently expanded in 2019, the plant occupies more than 45,000 sq. Ft., Including 9,000 sq. Ft. Of laboratories and 20,000 sq. Ft. Of manufacturing and packaging space — an investment totalling $45 million. The site is ISO 9001:2015 certified. The Good Production Practices (GPP) of Health Canada’s Cannabis Regulations have already been implemented, and, in 2022, Good Manufacturing Practices (GMP) standards will follow suit.